Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)
India
· Delayed Price · Currency is INR 554.50
+3.70 (0.67%)
Last updated: Jul 15, 2025
NSE:AKUMS Revenue
In the fiscal year ending March 31, 2025, Akums Drugs and Pharmaceuticals had annual revenue of 41.21B INR, down -1.45%. Akums Drugs and Pharmaceuticals had revenue of 10.59B in the quarter ending March 31, 2025, with 11.69% growth.
Revenue
41.21B
Revenue Growth
-1.45%
P/S Ratio
2.07
Revenue / Employee
5.47M
Employees
7,536
Market Cap
85.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 41.21B | -605.31M | -1.45% |
| Mar 31, 2024 | 41.82B | 5.24B | 14.34% |
| Mar 31, 2023 | 36.57B | -180.32M | -0.49% |
| Mar 31, 2022 | 36.75B | 9.49B | 34.81% |
| Mar 31, 2021 | 27.26B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Mankind Pharma | 122.07B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Glenmark Pharmaceuticals | 134.35B |
Akums Drugs and Pharmaceuticals News
- 6 months ago - Akums Drugs and Pharmaceuticals shares fall over 6% following Income Tax Department search - Business Upturn
- 7 months ago - Akums Drugs secures Rs 1,760 deal to supply oral liquid formulations in Europe - Business Upturn
- 8 months ago - Akums Drugs partners with Jagdale to revolutionize India’s Ready-to-Drink nutritional beverage market - Business Upturn
- 8 months ago - Akums Drugs shares surge 5% after signing Master Sales Agreement with Caregen - Business Upturn
- 8 months ago - Akums Drugs signs Master Sales Agreement with Caregen for Indian Nutraceutical market expansion - Business Upturn
- 8 months ago - Akums Drugs and Pharmaceuticals shares fall 5% following weak Q2 earnings outlook - Business Upturn
- 8 months ago - Akums Drugs and Pharmaceuticals Q2 FY25 results: Revenue at ₹1,033.09 crore, down 12.5% YoY; profit at ₹66.65 crore, up 103.8% YoY - Business Upturn
- 9 months ago - Akums Drugs signs MoU with Zambian Ministry of Health to manufacture local medicine - Business Upturn